Dr. John Cameron, Director, Global Head of Injectables Platform is interviewed by 247 BioPharma on the last day of DCAT 2025 in New York City.
He comments that CordenPharma had a very successful DCAT show after the DCAT forum announcement from our CEO and > 80 engaging meetings with customers over three days.
In terms of CordenPharma’s recent investments in Injectables, expansions include 2 main areas:
- Our R&D Lab will double in size to ~400 sq meters – to be finalized by Sept 2025 – and will allow efficient analysis of complex modalities and expand to include ~50 scientists, and
- We are constructing 2 new fillings lines based on isolator format to be online in 2027 which include a high-speed Pre-Filled Syringe (PFS) & cartridge filling line made by Syntegon, and a flexible filling line designed for Phase I-III and small-scale commercial material.
A great example of CordenPharma’s true end-to-end supply is our recent 11 March Press Release announcing our partnership with Viking Therapeutics, where Viking are developing an obesity drug called VK2735.
CordenPharma has entered a commercialization agreement with Viking to manufacture its Dual GLP-1/GIP Receptor Agonist peptide API, 200 million units of sterile injectables (including PFS, vials, and auto-injectors) and 1 billion units of oral solid tablets for its subcutaneous and oral peptide formulations respectively.
Dr. John Cameron
Global Platform Head Injectables
Related Articles
Want to find out more?
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.